Transvenous electrocardioversion is a growing and valid alternative to quinidine sulfate for treating atrial fibrillation in horses.
May support transvenous electrocardioversion for equine atrial fibrillation; leaves open need for randomized comparisons to quinidine.
Atrial fibrillation (AF) is the most common pathological cardiac arrhythmia in the horse. While it may be an incidental finding in some horses, it can be an important cause of poor exercise tolerance in the performance horse, especially those working at extremes of cardiac function. Although quinidine sulfate remains the most widely used treatment option for horses, alternatives, such as transvenous electrocardioversion, are growing in popularity. The decision-making process to establish the most appropriate treatment is based on a number of factors including chronicity, underlying disease, and cardiac size. The availability of transvenous electrocardioversion in the horse provides a valid alternative for the treatment of horses with atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Redpath et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: